SynbioTech Inc. (TPEX: 1295), a global innovator in probiotic and postbiotic research, proudly announces its remarkable achievements at the 39th World Genius Convention and Education Expo 2025 in Tokyo. Demonstrating excellence in scientific innovation and translational application, SynbioTech was awarded five Gold Medals and the prestigious Grand Special Award, underscoring the company’s leadership in precision nutrition and microbiome science.

Among the award-winning entries, LDL557, a postbiotic formulation developed for joint health, received both a Gold Medal and the highest honor of the Grand Special Award. This recognition highlights the product’s groundbreaking approach to modulating inflammation and protecting cartilage through microbiome pathways—establishing a new benchmark in joint health innovation.

Another Gold Medal recipient, ABKEFIR®, features a patented symbiotic fermentation process combining seven clinically selected probiotic strains. The formulation supports digestive health by generating beneficial organic acids and polysaccharides, helping inhibit harmful bacteria, promote beneficial flora, and reinforce the gut barrier.

In the area of renal health, SynForU®-ReMain was recognized for its ability to reduce gut-derived uremic toxin precursors while preserving gut barrier function. By targeting the gut-kidney axis, this innovation opens new avenues for microbiome-based approaches to managing kidney-related conditions.

Two formulations specifically developed for the China market—FS4722 and BY2—also earned Gold Medals. FS4722 demonstrated efficacy in regulating uric acid and reducing inflammation in preclinical models. BY2 showed promise in lipid management through bile salt resistance and cholesterol-binding capacity, addressing the increasing demand for solutions in metabolic health.

SynbioTech remains committed to advancing probiotic and postbiotic science across a wide spectrum of health applications—including gut health, immunity, healthy aging, joint mobility, metabolism, and urogenital wellness. These international accolades reaffirm the company’s mission to translate scientific breakthroughs into practical health applications and bring clinically proven innovations to the global market.




Reference:

1. Liu, Y., Lou, W., Li, M., Cui, H., Xu, P., & Wu, X. (2023). A strain of Lactiplantibacillus plantarum FS4722 and its application in uric acid reduction, weight management, and anti-inflammation (CN114507621B). China National Intellectual Property Administration.
2. Liu, Y., Lou, W., Cui, H., Li, M., Xu, P., & Wu, X. (2023). A cholesterol-lowering Lactobacillus paracasei BY2 and its applications (CN113699063B). China National Intellectual Property Administration.
3. SynbioTech Inc. (2022). Fermented composition containing ABKEFIR® multi-strain probiotics and its use in improving gut health (TWI770811B). Taiwan Intellectual Property Office.
4. SynbioTech Inc. (2022). Postbiotic composition for joint health based on strain LDL557 and its preparation method (TWI776433B). Taiwan Intellectual Property Office.
5. SynbioTech Inc. (2024). Probiotic formulation for renal health regulation via gut-kidney axis, comprising SynForU®-ReMain (TWI854384B). Taiwan Intellectual Property Office.